MALAT1 and glioblastoma: Kim et al. used anti-MALAT1 siRNA, encapsulated in a tumor-targeting and blood–brain barrier-crossing immunoliposome, to reduce the growth, migratory potential, and stemness of TMZ-resistant GBM cells, which was accompanied by their improved sensitivity to TMZ [165].